Platelets as Regulators of Inflammation in Cardiac Surgery

Completed

Conditions studied: Systemic Inflammatory Response Syndrome, Acute Kidney Injury

In brief

Platelets are increasingly recognized as a potent and ubiquitously present source of inflammatory activation. Importantly, antiplatelet therapy has been shown to significantly reduce major adverse events such as renal injury in cardiac surgery patients. However, in current practice, concerns of excessive bleeding-not platelet activation and thrombosis-shape clinical decisions. The investigators have recently seen, that a significant drop in platelet numbers following cardiac surgery is associated with increased mortality and risk of acute kidney injury. The investigators hypothesize that such thrombocytopenia is a result of excessive perioperative platelet activation and resultant release of inflammatory and tissue injurious signals by activated platelets. Platelet activation will be characterized during and after cardiac surgery and examine its correlation with inflammatory responses and perioperative end-organ injury.

Key facts

Study ID

NCT02568410

Run by

Duke University

People needed

99

Starts

2015-10-01

Expected to finish

2019-05-01

Last updated by the study team

2019-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• all patients undergoing elective CABG procedures

You may not qualify if…

• patients with a history of:
• renal injury (creatinine > 1.5 mg/dL)
• hepatic insufficiency (liver function tests > 1.5 times the upper limit of normal),
• severe pulmonary insufficiency (requiring home oxygen therapy),
• EF < 20%,
• IABP use preoperatively,
• liver, heart, or lung transplant

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.